Enzymatica publishes annual report for 2025

2026-04-14 10:00:00

The Annual Report for Enzymatica 2025 has been published today (in Swedish) on the company’s website: Finansiella rapporter - Enzymatica. The report is available only in digital format.

An English summary is available at: Financial reports - Enzymatica.

About Enzymatica

Enzymatica AB develops and markets products that treat and alleviate infections and symptoms in the upper airways. The best-selling product is ColdZyme®, an oral spray for colds and cold-like symptoms in the upper airways. The company's strategy is to continue growing by strengthening its position in existing markets and expanding into additional geographic markets through collaborations with established partners under their brands in the cold remedy market. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. The Certified Adviser is DNB Carnegie Investment Bank AB (publ).

For more information visit www.enzymatica.se